US court rules Acorda's Zanaflex capsules patent invalid
This article was originally published in Scrip
Executive Summary
A New Jersey judge has ruled that Apotex's proposed generic version of the spasticity drug Zanaflex (tizanidine HCl) capsules did not infringe Acorda Therapeutics' US patent, and that the patent is invalid. The move puts Apotex closer to a potential US launch, but Acorda says that it is evaluating its options, including a potential appeal of the decision.